New combo therapy aims to outsmart tough hodgkin lymphoma
NCT ID NCT04134325
First seen Apr 18, 2026 · Last updated May 09, 2026 · Updated 1 time
Summary
This small pilot study tests whether giving a PD-1 inhibitor after CAR-T cell therapy can improve outcomes for people with Hodgkin lymphoma that has come back or not responded to treatment. Ten adults who have already tried at least three prior therapies will receive standard anti-PD-1 treatment after their CAR-T cells stop working. The goal is to see if this sequence can trigger a stronger immune response and shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.